1
|
Bachy E, Le Gouill S, Sesques P, Di Blasi R, Guillaume M, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Castilla Llorente C, Choquet S, Casasnovas RO, Mothy M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Zerbit J, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F. S260: A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE LYSA STUDY FROM THE FRENCH DESCAR-T REGISTRY. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000843932.28141.4d] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
2
|
Polivka L, Parietti V, Bruneau J, Soucie E, Madrange M, Bayard E, Rignault R, Canioni D, Fraitag S, Lhermitte L, Feroul M, Tissandier M, Rossignol J, Frenzel L, Cagnard N, Meni C, Bouktit H, Collange AF, Gougoula C, Parisot M, Bader-Meunier B, Livideanu C, Laurent C, Arock M, Hadj-Rabia S, Rüther U, Dubreuil P, Bodemer C, Hermine O, Maouche-Chrétien L. The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis. Blood 2021; 138:2396-2407. [PMID: 34424959 DOI: 10.1182/blood.2020010207] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Accepted: 07/28/2021] [Indexed: 11/20/2022] Open
Abstract
Mastocytosis is a heterogeneous disease characterized by an abnormal accumulation of mast cells (MCs) in 1 or several organs. Although a somatic KIT D816V mutation is detected in ∼85% of patients, attempts to demonstrate its oncogenic effect alone have repeatedly failed, suggesting that additional pathways are involved in MC transformation. From 3 children presenting with both Greig cephalopolysyndactyly syndrome (GCPS, Mendelian Inheritance in Man [175700]) and congenital mastocytosis, we demonstrated the involvement of the hedgehog (Hh) pathway in mastocytosis. GCPS is an extremely rare syndrome resulting from haploinsufficiency of GLI3, the major repressor of Hh family members. From these familial cases of mastocytosis, we demonstrate that the Hh pathway is barely active in normal primary MCs and is overactive in neoplastic MCs. GLI3 and KIT mutations had a synergistic, tumorigenic effect on the onset of mastocytosis in a GCPS mouse model. Finally, Hh inhibitors suppressed neoplastic MC proliferation in vitro and extend the survival time of mice with aggressive systemic mastocytosis (ASM). This work revealed, for the first time, the involvement of Hh signaling in the pathophysiology of mastocytosis and demonstrated the cooperative effects of the KIT and Hh oncogenic pathways in mice with ASM, leading to the identification of new promising therapeutic targets.
Collapse
Affiliation(s)
- L Polivka
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, INSERM Unité Mixte de Recherche (UMR) 1163, Paris-Centre University, Imagine Institute, Paris, France
- Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
- Centre de Référence Maladies Rares des Mastocytoses (CEREMAST), Necker-Enfants Malades Hospital, Paris, France
| | - V Parietti
- Department of Animal Experimentation, Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - J Bruneau
- Department of Pathology, Hôpital Necker-Enfants Malades, AP-HP, Paris-Centre University, Paris, France
| | - E Soucie
- Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Marseille, France
| | - M Madrange
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, INSERM Unité Mixte de Recherche (UMR) 1163, Paris-Centre University, Imagine Institute, Paris, France
| | - E Bayard
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, INSERM Unité Mixte de Recherche (UMR) 1163, Paris-Centre University, Imagine Institute, Paris, France
| | - R Rignault
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, INSERM Unité Mixte de Recherche (UMR) 1163, Paris-Centre University, Imagine Institute, Paris, France
| | - D Canioni
- Department of Pathology, Hôpital Necker-Enfants Malades, AP-HP, Paris-Centre University, Paris, France
| | - S Fraitag
- Department of Pathology, Hôpital Necker-Enfants Malades, AP-HP, Paris-Centre University, Paris, France
| | - L Lhermitte
- Institut Necker-Enfants Malades, Université de Paris, INSERM Unité (U)1151, Paris, France
- Laboratory of Onco-Hematology, Hôpital Universitaire Necker Enfants-Malades, AP-HP, Paris, France
| | - M Feroul
- Institut Necker-Enfants Malades, Université de Paris, INSERM Unité (U)1151, Paris, France
- Laboratory of Onco-Hematology, Hôpital Universitaire Necker Enfants-Malades, AP-HP, Paris, France
| | - M Tissandier
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, INSERM Unité Mixte de Recherche (UMR) 1163, Paris-Centre University, Imagine Institute, Paris, France
| | - J Rossignol
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, INSERM Unité Mixte de Recherche (UMR) 1163, Paris-Centre University, Imagine Institute, Paris, France
- Centre de Référence Maladies Rares des Mastocytoses (CEREMAST), Necker-Enfants Malades Hospital, Paris, France
| | - L Frenzel
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, INSERM Unité Mixte de Recherche (UMR) 1163, Paris-Centre University, Imagine Institute, Paris, France
- Centre de Référence Maladies Rares des Mastocytoses (CEREMAST), Necker-Enfants Malades Hospital, Paris, France
- Department of Hematology, Necker-Enfants Malades Hospital, AP-HP, Paris-Centre University, Imagine Institute, Paris, France
| | - N Cagnard
- Bioinformatics, Platform Bioinformatics, INSERM U1163, Paris-Centre University, Imagine Institute, Paris, France
| | - C Meni
- Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - H Bouktit
- Centre de Référence Maladies Rares des Mastocytoses (CEREMAST), Necker-Enfants Malades Hospital, Paris, France
| | - A-F Collange
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, INSERM Unité Mixte de Recherche (UMR) 1163, Paris-Centre University, Imagine Institute, Paris, France
- Centre de Référence Maladies Rares des Mastocytoses (CEREMAST), Necker-Enfants Malades Hospital, Paris, France
| | - C Gougoula
- Central Unit for Animal Research and Animal Welfare Affairs (ZETT), Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany
| | - M Parisot
- Genomics Core Facility, Institut Imagine-Structure Fédérative de Recherche Necker, INSERM U1163 et INSERM US24/Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Service (UMS)3633, Paris-Centre University, Imagine Institute, Paris, France
| | - B Bader-Meunier
- Department of Pediatric Immunology and Hematology, Necker-Enfants Malades Hospital, AP-HP, INSERM U1163, Paris-Centre University, Paris, France
| | - C Livideanu
- Service de Dermatologie, CEREMAST, CHU de Toulouse
| | - C Laurent
- Service d'Anatomie-Pathologique, Oncopole, Centre Hospitalier de Universitaire (CJU) de Toulouse, Toulouse, France
| | - M Arock
- Centre de Référence Maladies Rares des Mastocytoses (CEREMAST), Necker-Enfants Malades Hospital, Paris, France
- Centre de Recherche des Cordeliers, INSERM Unité de Recherche Mixte en Santé (UMRS)1138, Paris, France
- Laboratory of Hematology, Pitié-Salpêtrière Hospital, AP-HP Sorbonne Université, Paris, France; and
| | - S Hadj-Rabia
- Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - U Rüther
- Institute of Animal Developmental and Molecular Biology, Heinrich Heine University, Düsseldorf, Germany
| | - P Dubreuil
- Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Marseille, France
| | - C Bodemer
- Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
- Centre de Référence Maladies Rares des Mastocytoses (CEREMAST), Necker-Enfants Malades Hospital, Paris, France
| | - O Hermine
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, INSERM Unité Mixte de Recherche (UMR) 1163, Paris-Centre University, Imagine Institute, Paris, France
- Centre de Référence Maladies Rares des Mastocytoses (CEREMAST), Necker-Enfants Malades Hospital, Paris, France
- Department of Hematology, Necker-Enfants Malades Hospital, AP-HP, Paris-Centre University, Imagine Institute, Paris, France
| | - L Maouche-Chrétien
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, INSERM Unité Mixte de Recherche (UMR) 1163, Paris-Centre University, Imagine Institute, Paris, France
- Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
- Centre de Référence Maladies Rares des Mastocytoses (CEREMAST), Necker-Enfants Malades Hospital, Paris, France
| |
Collapse
|
3
|
Najm A, Alunno A, Machado P, Bertheussen H, Burmester G, Carubbi F, De Marco G, Giacomelli R, Hermine O, Isaacs J, Koné-Paut I, Magro-Checa C, McInnes I, Meroni P, Quartuccio L, Athimalaipet V, Ramos-Casals M, Rodríguez-Carrio J, Schultze-Koops H, Stamm T, Tas S, Terrier B, McGonagle D, Mariette X. Mise à jour des recommandations EULAR sur l’utilisation des thérapies immunomodulatrices dans la prise en charge de la Covid-19. Revue du Rhumatisme 2021. [PMCID: PMC8626108 DOI: 10.1016/j.rhum.2021.10.349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 10/29/2022]
|
4
|
Ballul T, Sabato V, Bulai Livideanu C, Neuraz A, Lemal R, Tournilhac O, Terriou L, Launay D, Bouillet L, Gourguechon C, Damaj G, Durupt S, Frenzel L, Bouktit H, Gousseff M, Le Mouel E, Barète S, Hermine O, Lortholary O, Rossignol J. Caractérisation d’une nouvelle entité de maladie mastocytaire primaire associée à l’ostéoporose précoce et à l’anaphylaxie idiopathique: accumulation mastocytaire médullaire avec retentissement clinique (MMRC). Étude internationale du CEREMAST. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
5
|
Cheminant M, Burroni B, Bris Y, Chartier L, Oberic L, Ribrag V, Delfau M, Thieblemont C, Gressin R, Canioni D, Peyre M, Laurent C, Steimle T, Kaltenbach S, Asnafi V, Macintyre E, Callanan M, Gouill S, Hermine O. HIGH‐RISK MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.64_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Cheminant
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - B. Burroni
- Cochin University Hospital Pathology Paris France
| | - Y. Bris
- Nantes University Hospital Hematolobiology Nantes France
| | | | - L. Oberic
- Toulouse‐Oncopole University hospital Hematology Toulouse France
| | - V. Ribrag
- Gustave‐Roussy Hematology Villejuif France
| | - M.‐H. Delfau
- Mondor University Hospital Hematolobiology Créteil France
| | | | - R. Gressin
- Grenoble University Hospital Hematology Grenoble France
| | - D. Canioni
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - M. Peyre
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | | | - T. Steimle
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - S. Kaltenbach
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - V. Asnafi
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - E. Macintyre
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - M. Callanan
- Dijon University Hospital Hematobiology Dijon France
| | - S. Gouill
- Nantes University Hospital Hematology Nantes France
| | - O. Hermine
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| |
Collapse
|
6
|
Villa D, Hoster E, Hermine O, Klapper W, Szymczyk M, Bosly A, Unterhalt M, Freeman CL, Scott DW, Gerrie AS, Savage KJ, Sehn LH, Dreyling M. RITUXIMAB IN COMBINATION WITH BENDAMUSTINE OR HIGH‐DOSE CYTARABINE‐BASED INDUCTION THERAPY IN TRANSPLANT‐ELIGIBLE PATIENTS WITH MANTLE CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.62_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- D. Villa
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - E. Hoster
- Ludwig‐Maximilians‐Universität München Institute for Medical Information Processing, Biometry, and Epidemiology Munich Germany
| | - O. Hermine
- University of Paris Descartes, Hôpital Necker Assistance Publique Hôpitaux de Paris Paris France
| | - W. Klapper
- Universitätsklinikum Schleswig‐Holstein Institut für Pathologie, Sektion Hämatopathologie und Lymphknotenregister Kiel Germany
| | - M. Szymczyk
- Maria Sklodowska‐Curie National Research Institute of Oncology Department of Lymphoid Malignancies Warsaw Poland
| | - A. Bosly
- CHU UCL Mont‐Godinne‐Dinant Faculty of Medicine and Dentistry Yvoir Belgium
| | - M. Unterhalt
- University of Ulm Department of Internal Medicine Ulm Germany
| | - C. L. Freeman
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - D. W. Scott
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - A. S. Gerrie
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - K. J. Savage
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - L. H. Sehn
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - M. Dreyling
- Ludwig‐Maximilians‐Universität München Medizinische Klinik III Munich Germany
| |
Collapse
|
7
|
Rossignol J, Marzac C, Dellal A, Solary E, Jachiet V, Belfeki N, Slaoui M, Georgin-Lavialle S, Benarroche D, Hermine O, Fain O, Mekinian A. Mutation du gène UBA1 dans l’artérite à cellules géantes. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.03.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
8
|
Jendoubi F, Shourick J, Negretto M, Laurent C, Apoil PA, Evrard S, Mansat-De Mas V, Severino-Freire M, Mailhol C, Degboé Y, Dubreuil P, Hermine O, Paul C, Bulai Livideanu C. Cutaneous mastocytosis in adults with a serum tryptase level < 20 ng mL -1 : why we should investigate further. Br J Dermatol 2021; 185:453-455. [PMID: 33811770 DOI: 10.1111/bjd.20098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2021] [Revised: 03/30/2021] [Accepted: 03/31/2021] [Indexed: 11/27/2022]
Affiliation(s)
- F Jendoubi
- Departments of, Department of, Dermatology, Toulouse University Hospital, Paul Sabatier University, Reference Centre for Mastocytosis (CEREMAST) Toulouse, Toulouse, France
| | - J Shourick
- Department of Epidemiology, Toulouse University Hospital, Paul Sabatier University, Toulouse, France
| | - M Negretto
- Departments of, Department of, Dermatology, Toulouse University Hospital, Paul Sabatier University, Reference Centre for Mastocytosis (CEREMAST) Toulouse, Toulouse, France
| | - C Laurent
- Department of, Anatomy and Pathological Cytology of Prof. Brousset, Toulouse University Hospital, Paul Sabatier University, Reference Centre for Mastocytosis (CEREMAST) Toulouse, Toulouse, France
| | - P A Apoil
- Immunology Clinical Laboratory, CEREMAST Toulouse, Toulouse, France
| | - S Evrard
- Department of, Anatomy and Pathological Cytology of Prof. Brousset, Toulouse University Hospital, Paul Sabatier University, Reference Centre for Mastocytosis (CEREMAST) Toulouse, Toulouse, France
| | - V Mansat-De Mas
- Department of Haematology, CEREMAST Toulouse, Toulouse, France
| | - M Severino-Freire
- Departments of, Department of, Dermatology, Toulouse University Hospital, Paul Sabatier University, Reference Centre for Mastocytosis (CEREMAST) Toulouse, Toulouse, France
| | - C Mailhol
- Department of Pneumo-allergology, CEREMAST Toulouse, Toulouse, France
| | - Y Degboé
- Department of Rheumatology, CEREMAST Toulouse, Toulouse University Hospital and Paul Sabatier University and INSERM UMR1043, Toulouse, France
| | - P Dubreuil
- CRCM, [CEREMAST, Marseille, Equipe Labellisée Ligue Contre le Cancer], INSERM, Institut Paoli-Calmettes, Aix-Marseille University, CNRS, Marseille, France
| | - O Hermine
- Haematology, CEREMAST Necker, AP-HP, Paris, France
| | - C Paul
- Departments of, Department of, Dermatology, Toulouse University Hospital, Paul Sabatier University, Reference Centre for Mastocytosis (CEREMAST) Toulouse, Toulouse, France
| | - C Bulai Livideanu
- Departments of, Department of, Dermatology, Toulouse University Hospital, Paul Sabatier University, Reference Centre for Mastocytosis (CEREMAST) Toulouse, Toulouse, France
| |
Collapse
|
9
|
Affiliation(s)
- Q Richier
- Service de maladies infectieuses, hôpital Saint-Antoine, Assistance publique des Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
| | - L Plaçais
- Service d'hématologie, hôpital Necker, Assistance publique des Hôpitaux de Paris, Paris, France; Sorbonne université, Paris, France
| | - K Lacombe
- Service de maladies infectieuses, hôpital Saint-Antoine, Assistance publique des Hôpitaux de Paris, Paris, France; Sorbonne université, Paris, France
| | - O Hermine
- Université de Paris, Paris, France; Service d'hématologie, hôpital Necker, Assistance publique des Hôpitaux de Paris, Paris, France; Inserm U 1163, institut Imagine, Paris, France
| |
Collapse
|
10
|
Lacout C, Fouquet G, Terriou L, Millot G, Lavigne C, Orvain C, Dhôte R, Hamel J, Bloch-Queyrat C, Hermine O, Urbanski G. Risque infectieux de l’étoposide dans l’hémophagocytose lymphohistiocytaire de l’adulte. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Bugaut H, Maillard H, Jacobzone C, Le Pelletier F, Charlotte F, Arock M, Dubreuil P, Bulai Livideanu C, Hermine O, Barete S. La cladribine améliore les manifestations cutanées, la qualité de vie dermatologique et spécifique des patients adultes avec mastocytose : étude rétrospective de 16 patients du CEREMAST. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Maincent O, Polivka L, Canioni D, Fraitag S, Maouche-Chrétien L, Hermine O, Hadj-Rabia S, Bodemer C. Mastocytose systémique congénitale sévère associée à des mutations KIT et EZH2. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Urbanski G, Terriou L, Fouquet G, Hamel J, Lavigne C, Orvain C, Larroche C, Hermine O, Bloch-Queyrat C, Lacout C. Facteurs associés à la mortalité à J30 dans l’hémophagocytose lymphohistiocytaire chez l’adulte : construction d’un score de mortalité à partir d’une cohorte multicentrique de 170 patients et validation sur une cohorte de 118 patients. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Polivka L, Parietti V, Soucie E, Bayard E, Canioni D, Fraitag S, Lhermitte L, Tissandier M, Rossignol J, Cagnard N, Bader-Meunier B, Arock M, Hadj-Rabia S, Dubreuil P, Bodemer C, Hermine O, Maouche-Chrétien L. Implication de la voie de signalisation Hedgehog dans les mastocytoses. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Papo M, Corneau A, Cohen F, Robin B, Emile JF, Miyara M, Blanc C, Amoura Z, Hermine O, Haroche J, Trovati Maciel T. AB0038 IMMUNE PHENOTYPING OF ERDHEIM-CHESTER DISEASE THROUGH MASS CYTOMETRY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:The understanding of Erdheim-Chester Disease (ECD) pathogenesis has been greatly improved these past few years with the discovery of activating MAPK pathway mutations in most of ECD patients. However, the inflammatory phenotype of ECD remains widely unknown.Objectives:We aimed to explore the inflammatory phenotype of Erdheim-Chester disease (ECD) using mass cytometry.Methods:We analyzed peripheral blood mononuclear cells from 13 ECD patients and 11 healthy donors (HD) using mass cytometry with 29 metal-conjugated antibodies.Results:Compared to HD, untreated ECD patients had increased proportion of classical monocytes (90.8 [87.1-96.5] vs 81.6 [76.2-87.5] %, p=0.02) and decreased proportion of non-classical monocytes (4.7 [3.4-9.7] vs 11.8 [6.6-17.2] %, p=0.047). Untreated ECD patients had more circulating Th17 cells compared to HD (3.3 [3-5.3] vs 1.3 [0.4-2.3] %, p=0.015) and ECD patients treated with BRAF or MEK inhibitors (3.3 (3-5.3] vs 1.9 [0.6-2.4] %, p=0.005). Moreover Treg cells were lower in ECD patients than HD, with an increased Th17/Treg ratio (1.37 [0.74-1.9] vs 0.34 [0.19-0.43], p=0.0004). There was no difference regarding Th1 cells, Th2 cells, B cells, NK cells and circulating dendritic cells.Conclusion:ECD monocyte profile seems similar to what have been described in CMML. Inflammation observed in ECD may be driven through Th17 cells, and might be targeted with specific treatment.Disclosure of Interests:None declared
Collapse
|
16
|
Bulai Livideanu C, Severino-Freire M, Jendoubi F, Tournier E, Commont T, Hermine O, Paul C. Image Gallery: The vulva: an atypical localization of mastocytosis in adulthood. Br J Dermatol 2019; 181:e33. [PMID: 31240694 DOI: 10.1111/bjd.17897] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- C Bulai Livideanu
- Reference Centre for Mastocytosis (CEREMAST) Toulouse, Department of Dermatology, Toulouse, France
| | - M Severino-Freire
- Reference Centre for Mastocytosis (CEREMAST) Toulouse, Department of Dermatology, Toulouse, France
| | - F Jendoubi
- Reference Centre for Mastocytosis (CEREMAST) Toulouse, Department of Dermatology, Toulouse, France
| | - E Tournier
- CEREMAST Toulouse, Department of Anatomy and Pathological Cytology of Prof. Brousset, Toulouse, France
| | - T Commont
- Department of Internal Medicine, Oncopole, Toulouse University Hospital, Paul Sabatier University, Toulouse, France
| | - O Hermine
- CEREMAST Necker, Haematology, AP-HP, Paris, France
| | - C Paul
- Reference Centre for Mastocytosis (CEREMAST) Toulouse, Department of Dermatology, Toulouse, France
| |
Collapse
|
17
|
Baldacini M, Burroni B, Le Gouill S, Gressin R, Hermine O, Traverse-glehen A, Martin A, Moreau A, Bene M, Fogarty P, Canioni D, Fornecker L. CLINICO-BIOLOGICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR AGRESSIVE MANTLE CELL LYMPHOMA PATIENTS INCLUDED IN CLINICAL TRIALS. A LYSA STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.48_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M. Baldacini
- Hematology Department; Strasbourg University Hospital; Strasbourg France
| | - B. Burroni
- Pathology Department; Cochin University Hospital, Assistance Publique-Hopitaux de Paris (APHP); Paris France
| | - S. Le Gouill
- Hematology Department; Nantes University Hospital; Nantes France
| | - R. Gressin
- Hematology Department; Grenoble University Hospital; La Tronche France
| | - O. Hermine
- Hematology Department; Necker University Hospital, Assistance Publique-Hopitaux de Paris (APHP); Paris France
| | - A. Traverse-glehen
- Pathology Department; Lyon University Hospital, Hospices Civil de Lyon; Lyon France
| | - A. Martin
- Pathology Department; Avicenne Hospital, Assistance Publique-Hôpitaux de Paris; Bobigny France
| | - A. Moreau
- Pathology Department; Nantes University Hospital; Nantes France
| | - M. Bene
- Hematology Biology; Nantes University Hospital; Nantes France
| | - P. Fogarty
- Lymphoma Academic Research Organisation (LYSARC); Centre Hospitalier Lyon Sud; Pierre-Bénite France
| | - D. Canioni
- Pathology Department; Necker University Hospital, Assistance Publique-Hôpitaux de Paris (APHP); Paris France
| | - L. Fornecker
- Hematology Department; Strasbourg University Hospital; Strasbourg France
| |
Collapse
|
18
|
Le Gouill S, Beldi-Ferchiou A, Cacheux V, Salles G, Canioni D, Bodet-Milin C, Alcantara M, Delwail V, Gastinne T, Thieblemont C, Maisonneuve H, Lamy de la Chapelle T, Oberic L, Bouabdallah K, Ribrag V, Delfau-Larue M, Macintyre E, Hermine O. OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA-101 TRIAL, A LYSA GROUP STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.14_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | - V. Cacheux
- Hematologie; CHU Clermont-Ferrand; Clermont-Ferrand France
| | | | | | | | | | - V. Delwail
- Hematology Biology; CHU Poitiers; Poitiers France
| | | | | | - H. Maisonneuve
- Hematology-Oncology; CH Roche-Sur-Yon; Roche-Sur-Yon France
| | | | - l. Oberic
- Hematology; Oncopole de Toulouse; Toulouse France
| | | | - V. Ribrag
- Hematology; Institut Gustave Roussy; Villejuif France
| | | | - E. Macintyre
- Hématologie Biologique; Hôpital Necker; Paris France
| | - O. Hermine
- Hematologie; Hôpital Necker; Paris France
| |
Collapse
|
19
|
Cheminant M, Decroos A, Bruneau J, Carras S, Pelletier L, Martin N, Peri V, Guillot F, Paturel C, Sicard H, Bonnafous C, Lhermitte L, Molina T, Asnafi V, Genestier L, Gaulard P, Ortonne N, Hermine O. KIR3DL2 IS EXPRESSED IN PERIPHERAL T-CELL LYMPHOMAS AND MAY BE A THERAPEUTIC TARGET. Hematol Oncol 2019. [DOI: 10.1002/hon.21_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Cheminant
- Clinical Hematology; Necker University Hospital; Paris AP-HP France
| | - A. Decroos
- INSERM U955; Université Paris-Est; Créteil France
| | - J. Bruneau
- Pathology Department; Necker University Hospital; Paris AP-HP France
| | - S. Carras
- Centre de Rercherche en Cancérologie de Lyon (CRCL); INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon I; Lyon France
| | - L. Pelletier
- INSERM U955; Université Paris-Est; Créteil France
| | - N. Martin
- INSERM U955; Université Paris-Est; Créteil France
| | - V. Peri
- Innate Pharma; Innate Pharma; Marseille France
| | - F. Guillot
- Innate Pharma; Innate Pharma; Marseille France
| | - C. Paturel
- Innate Pharma; Innate Pharma; Marseille France
| | - H. Sicard
- Innate Pharma; Innate Pharma; Marseille France
| | | | - L. Lhermitte
- Biological Hematology; Necker University Hospital; Paris AP-HP France
| | - T. Molina
- Pathology Department; Necker University Hospital; Paris AP-HP France
| | - V. Asnafi
- Biological Hematology; Necker University Hospital; Paris AP-HP France
| | - L. Genestier
- Centre de Rercherche en Cancérologie de Lyon (CRCL); INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon I; Lyon France
| | - P. Gaulard
- Pathology department; Groupe Hospitalier Henri Mondor; Créteil AP-HP France
| | - N. Ortonne
- Pathology department; Groupe Hospitalier Henri Mondor; Créteil AP-HP France
| | - O. Hermine
- Clinical Hematology; Necker University Hospital; Paris AP-HP France
| |
Collapse
|
20
|
Degboé Y, Eischen M, Apoil PA, Mailhol C, Dubreuil P, Hermine O, Paul C, Bulai Livideanu C, Laroche M. Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome. Osteoporos Int 2019; 30:1235-1241. [PMID: 30847528 DOI: 10.1007/s00198-019-04918-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Accepted: 02/26/2019] [Indexed: 01/08/2023]
Abstract
UNLABELLED Little is known about osteoporosis in mast cell disorders (MCDs) not related to systemic mastocytosis. We described osteoporosis and fractures in MCDs and showed that systemic mastocytosis was the only studied MCDs associated with osteoporotic vertebral fractures. INTRODUCTION To describe osteoporosis (OP) and fragility fractures in mast cell disorders (MCDs). METHODS We retrospectively analyzed data concerning all successive patients with systemic mastocytosis (SM), cutaneous mastocytosis (CM), and mast cell activation syndromes (MCAS) diagnosed in our mastocytosis expert center between 2004 and 2015. We collected data concerning demographic profiles, clinical signs of MCD, osteoporosis, fractures, densitometry, and biological assessment of MCD. We compared CM and MCAS patients with SM patients with regard to the characteristics of OP and fragility fractures. RESULTS We assessed 89 SM patients, 20 CM patients, and 20 MCAS patients. Osteoporosis was less frequent in CM (15.0%) and MCAS (10.0%) than in SM (44.9%). Similarly, fractures were less frequent in non-SM MCDs, respectively 5.0%, 5.0%, and 28.1%. SM patients displayed high prevalence of vertebral fractures (22.5%), mostly multiple. Conversely, in non-SM patients, vertebral fractures appeared to be uncommon (5%) and more frequently associated with risk factors for osteoporosis. CONCLUSIONS SM is associated with multiple vertebral osteoporotic fractures, whereas CM and MCAS do not appear to be associated with this phenotype.
Collapse
Affiliation(s)
- Y Degboé
- Rheumatology Centre, Pierre Paul Riquet Hospital, Toulouse University Hospital & Paul Sabatier University, 1 Place du Dr Baylac, 31059, Toulouse, France.
- Center for Pathophysiology of Toulouse Purpan, INSERM UMR 1043, CHU Purpan, Toulouse, France.
| | - M Eischen
- Rheumatology Centre, Pierre Paul Riquet Hospital, Toulouse University Hospital & Paul Sabatier University, 1 Place du Dr Baylac, 31059, Toulouse, France
| | - P A Apoil
- Department of Immunology, Rangueil Hospital, Toulouse University Hospital, Toulouse, France
| | - C Mailhol
- Department of Pneumo-allergology, Larrey Hospital, Toulouse University Hospital, Toulouse, France
| | - P Dubreuil
- Cancer Research Center of Marseille, INSERM , Institut Paoli Calmettes & CNRS, CEREMAST, Label Ligue Contre le Cancer, Aix Marseille University, Marseille, France
| | - O Hermine
- Department of Hematology, CEREMAST, Label Ligue Contre le Cancer, Université Paris Descartes & Hôpital Necker Enfants Malades & Assistance Publique Hôpitaux de Paris, Paris, France
| | - C Paul
- Department of Dermatology, Mastocytosis Expert Centre of Midi-Pyrénées, Toulouse University Hospital & Paul Sabatier University, Toulouse, France
| | - C Bulai Livideanu
- Department of Dermatology, Mastocytosis Expert Centre of Midi-Pyrénées, Toulouse University Hospital & Paul Sabatier University, Toulouse, France
| | - M Laroche
- Rheumatology Centre, Pierre Paul Riquet Hospital, Toulouse University Hospital & Paul Sabatier University, 1 Place du Dr Baylac, 31059, Toulouse, France
| |
Collapse
|
21
|
Cheminant M, Lhermitte L, Bruneau J, Sicard H, Bonnafous C, Ortonne N, Genestier L, Gaulard P, Palmic P, Dussiot M, Waast L, Avettand-Fenoel V, Brouzes C, Lepelletier Y, Asnafi V, Marçais A, Hermine O. MEMBRANE EXPRESSION OF NK RECEPTOR KIR3DL2 CONTRIBUTES TO DELINEATE THE ACUTE-TYPE AND IS A THERAPEUTIC TARGET IN ADULT T-CELL LEUKEMIA/LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.82_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Cheminant
- Clinical Hematology; Necker University Hospital, AP-HP; Paris France
| | - L. Lhermitte
- Biological Hematology; Necker University Hospital, AP-HP; Paris France
| | - J. Bruneau
- Pathology Department; Necker University Hospital, AP-HP; Paris France
| | | | | | - N. Ortonne
- Pathology; Groupe Hospitalier Henri Mondor, AP-HP; Créteil France
| | - L. Genestier
- Centre Léon Bérard; Université Claude Bernard Lyon I, Lyon, France, Centre de Rercherche en Cancérologie de Lyon (CRCL), INSERM U1052-CNRS UMR5286; Lyon France
| | - P. Gaulard
- Pathology; Groupe Hospitalier Henri Mondor, AP-HP; Créteil France
| | - P. Palmic
- Pathology Department; Necker University Hospital, AP-HP; Paris France
| | - M. Dussiot
- INSERM UMR 1163; Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute; Paris France
| | - L. Waast
- INSERM U1016; CNRS UMR 8104, Université Paris Descartes, Sorbonne Paris Cité, Institut Cochin; Paris France
| | | | - C. Brouzes
- Biological Hematology; Necker University Hospital, AP-HP; Paris France
| | - Y. Lepelletier
- INSERM UMR 1163; Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute; Paris France
| | - V. Asnafi
- Biological Hematology; Necker University Hospital, AP-HP; Paris France
| | - A. Marçais
- Clinical Hematology; Necker University Hospital, AP-HP; Paris France
| | - O. Hermine
- Clinical Hematology; Necker University Hospital, AP-HP; Paris France
| |
Collapse
|
22
|
Fradet M, Negretto M, Tournier E, Laurent C, Apoil PA, Evrard S, Degboe Y, Del Mas V, Lamant L, Dubreuil P, Laroche M, Mailhol C, Hermine O, Paul C, Bulai Livideanu C. Frequency of isolated cutaneous involvement in adult mastocytosis: a cohort study. J Eur Acad Dermatol Venereol 2019; 33:1713-1718. [PMID: 31009132 DOI: 10.1111/jdv.15638] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2019] [Accepted: 04/09/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND Mastocytosis is characterized by the accumulation/proliferation of abnormal mast cells. The frequency of isolated cutaneous involvement in adults with mastocytosis has not been fully determined. The main objective of our study was to assess the frequency of isolated cutaneous mastocytosis (CM) in adults with mastocytosis skin lesions. The second objective was to compare the clinical, histological, biological and imaging features in patients with isolated CM and patients with systemic mastocytosis (SM). METHODS We included all patients with histology-proven mastocytosis skin lesions between January 2009 and December 2017. The mastocytosis diagnosis was made according to the international diagnostic criteria. All data were collected from a dedicated specific case report. RESULTS Among 160 patients with mastocytosis skin lesions, 25 patients had isolated CM (15.6%), 105 had SM and 30 (18.7%) patients had undetermined mastocytosis. Skin KIT mutation (OR: 51.9, 95% CI: 3.9-678, P = 0.001) and high bone marrow tryptase (OR: 97.4, 95% CI: 10.3-915, P = 0.001) were strong predictors of SM. The prevalence of osteoporosis was higher in the SM population than in the isolated CM population. Moreover, a decrease in bone mineral density over a short period of follow-up (1-2 years) was associated with SM. There were no differences between the two groups regarding the frequency of mast cell activation symptoms, the presentation of skin lesions, the number of mast cells in the dermis and the level of serum tryptase. We propose considering the KIT mutation status and bone marrow tryptase levels to aid the diagnosis of isolated CM in adult mastocytosis patients. CONCLUSION Only a small minority of adults with mastocytosis skin lesions has isolated cutaneous involvement. In 18.7% of mastocytosis cases, even complete workup does not allow for a precise classification of patients.
Collapse
Affiliation(s)
- M Fradet
- Reference Centre for Mastocytosis (CEREMAST) Toulouse, Department of Dermatology, Toulouse University Hospital, Paul Sabatier University, Toulouse, France
| | - M Negretto
- Reference Centre for Mastocytosis (CEREMAST) Toulouse, Department of Dermatology, Toulouse University Hospital, Paul Sabatier University, Toulouse, France
| | - E Tournier
- Department of Anatomy and Pathological Cytology of Prof. Brousset, Toulouse University Hospital, Paul Sabatier University, CEREMAST Toulouse, Toulouse, France
| | - C Laurent
- Department of Anatomy and Pathological Cytology of Prof. Brousset, Toulouse University Hospital, Paul Sabatier University, CEREMAST Toulouse, Toulouse, France
| | - P A Apoil
- Immunology Clinical Laboratory, CEREMAST Toulouse, Toulouse, France
| | - S Evrard
- Department of Anatomy and Pathological Cytology of Prof. Brousset, Toulouse University Hospital, Paul Sabatier University, CEREMAST Toulouse, Toulouse, France
| | - Y Degboe
- Department of Rheumatology, CEREMAST Toulouse, Toulouse, France
| | - V Del Mas
- Department of Haematology, CEREMAST Toulouse, Toulouse, France
| | - L Lamant
- Department of Anatomy and Pathological Cytology of Prof. Brousset, Toulouse University Hospital, Paul Sabatier University, CEREMAST Toulouse, Toulouse, France
| | - P Dubreuil
- CRCM, [CEREMAST, Marseille, Equipe Labellisée Ligue Contre le Cancer], Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ, CNRS, Marseille, France
| | - M Laroche
- Department of Rheumatology, CEREMAST Toulouse, Toulouse, France
| | - C Mailhol
- Department of Pneumo-allergology, CEREMAST Toulouse, Toulouse, France
| | - O Hermine
- Haematology, CEREMAST Necker, AP-HP, Paris, France
| | - C Paul
- Reference Centre for Mastocytosis (CEREMAST) Toulouse, Department of Dermatology, Toulouse University Hospital, Paul Sabatier University, Toulouse, France
| | - C Bulai Livideanu
- Reference Centre for Mastocytosis (CEREMAST) Toulouse, Department of Dermatology, Toulouse University Hospital, Paul Sabatier University, Toulouse, France
| |
Collapse
|
23
|
Poirier E, Fraitag S, Tezenas du Montcel S, Moguelet P, Charlotte F, Lortholary O, Hermine O, Canioni D, Barete S. CD30 expression in cutaneous lesions of systemic mastocytosis: clinical, biological and histopathological analysis of 27 patients. J Eur Acad Dermatol Venereol 2019; 33:e344-e347. [DOI: 10.1111/jdv.15633] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- E. Poirier
- Unité Fonctionnelle de Dermatologie Groupe Hospitalier Pitié‐Salpêtrière, AP‐HP UPMC Université Paris 06 Sorbonne Université Paris France
| | - S. Fraitag
- Centre National de Référence des Mastocytoses AP‐HP CEREMAST Paris France
- Service d'Anatomopathologie Hôpital Necker AP‐HP Université Paris‐Sorbonne Paris France
| | - S. Tezenas du Montcel
- UMR S 1136, INSERM U 1136 Institut Pierre Louis d’Épidémiologie et de Santé Publique UPMC Université Paris 06 Sorbonne Université Paris France
- Unité de Biostatistiques Groupe Hospitalier Pitié‐Salpêtrière AP‐HP Paris France
| | - P. Moguelet
- Service d'Anatomopathologie Hôpital Tenon, AP‐HP UPMC Université Paris 06 Sorbonne Universités Paris France
| | - F. Charlotte
- Service d'Anatomopathologie Groupe Hospitalier Pitié Salpêtrière, AP‐HP UPMC Université Paris 06 Sorbonne Université Paris France
| | - O. Lortholary
- Centre National de Référence des Mastocytoses AP‐HP CEREMAST Paris France
- Service d'Infectiologie Hôpital Necker AP‐HP Université Paris‐Sorbonne Paris France
| | - O. Hermine
- Centre National de Référence des Mastocytoses AP‐HP CEREMAST Paris France
- Service d'Hématologie Hôpital Necker AP‐HP Université Paris‐Sorbonne Paris France
| | - D. Canioni
- Centre National de Référence des Mastocytoses AP‐HP CEREMAST Paris France
- Service d'Anatomopathologie Hôpital Necker AP‐HP Université Paris‐Sorbonne Paris France
| | - S. Barete
- Unité Fonctionnelle de Dermatologie Groupe Hospitalier Pitié‐Salpêtrière, AP‐HP UPMC Université Paris 06 Sorbonne Université Paris France
- Centre National de Référence des Mastocytoses AP‐HP CEREMAST Paris France
| | | |
Collapse
|
24
|
Couronné L, Bachy E, Roulland S, Nadel B, Davi F, Armand M, Canioni D, Michot JM, Visco C, Arcaini L, Besson C, Hermine O. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol 2019; 29:92-100. [PMID: 29045541 DOI: 10.1093/annonc/mdx635] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
In addition to liver disorders, hepatitis C virus (HCV) is also associated with extrahepatic immune manifestations and B-cell non-Hodgkin lymphoma (NHL), especially marginal zone lymphoma, de novo or transformed diffuse large B-cell lymphoma and to a lesser extent, follicular lymphoma. Epidemiological data and clinical observations argue for an association between HCV and lymphoproliferative disorders. The causative role of HCV in NHL has been further supported by the response to antiviral therapy. Pathophysiological processes at stake leading from HCV infection to overt lymphoma still need to be further elucidated. Based on reported biological studies, several mechanisms of transformation seem however to emerge. A strong body of evidence supports the hypothesis of an indirect transformation mechanism by which sustained antigenic stimulation leads from oligoclonal to monoclonal expansion and sometimes to frank lymphoma, mostly of marginal zone subtype. By infecting lymphocytes, HCV could play a direct role in cellular transformation, particularly in de novo large B-cell lymphoma. Finally, HCV is associated with follicular lymphoma in a subset of patients. In this setting, it may be hypothesized that inflammatory cytokines stimulate proliferation and transformation of IgH-BCL2 clones that are increased during chronic HCV infection. Unraveling the pathogenesis of HCV-related B-cell lymphoproliferation is of prime importance to optimize therapeutic strategies, especially with the recent development of new direct-acting antiviral drugs.
Collapse
Affiliation(s)
- L Couronné
- Department of Hematology, Assistance Publique-Hôpitaux de Paris (APHP), Necker Hospital, Paris, France.,INSERM UMR 1163, CNRS ERL 8254, Imagine Institute, Paris, France.,Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - E Bachy
- Cancer Research Center of Lyon, INSERM U1052, CNRS UMR 5286, Lyon, France.,Department of Hematology, Lyon Sud Hospital, Lyon, France
| | - S Roulland
- Center of Immunology of Marseille-Luminy, Aix Marseille University, Marseille, France
| | - B Nadel
- Center of Immunology of Marseille-Luminy, Aix Marseille University, Marseille, France
| | - F Davi
- INSERM U1104, Marseille, France.,CNRS UMR 7280, Marseille, France.,Department of Hematology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University, Paris, France
| | - M Armand
- INSERM U1104, Marseille, France.,CNRS UMR 7280, Marseille, France.,Department of Hematology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University, Paris, France
| | - D Canioni
- Department of Pathology, Necker Hospital, AP-HP, Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - J M Michot
- Department of Hematology and Drug Development, Gustave Roussy Institute, Villejuif; France
| | - C Visco
- Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
| | - L Arcaini
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.,Departement of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - C Besson
- Department of Hematology and Oncology, Hospital of Versailles, Le Chesnay, France.,University of Versailles Saint Quentin en Yvelines, Paris-Saclay University, Communauté Paris-Saclay, Paris, France.,INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre, France
| | - O Hermine
- Department of Hematology, Assistance Publique-Hôpitaux de Paris (APHP), Necker Hospital, Paris, France.,INSERM UMR 1163, CNRS ERL 8254, Imagine Institute, Paris, France.,Paris Descartes-Sorbonne Paris Cité University, Paris, France
| |
Collapse
|
25
|
Allali S, Lionnet F, Mattioni S, Bachmeyer C, Arlet J, Brousse V, De Montalembert M, Chalumeau M, Grateau G, Hermine O, Launay J, Georgin Lavialle S. Augmentation des taux plasmatiques d’histamine chez les patients atteints de drépanocytose. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Lewinski A, Foucher A, Regent A, Marcais A, Duquenne S, Ortonne N, Hermine O, Klisnick J, Cabrera Q, Bertolotti A. Leucémie/lymphome T de l’adulte à HTLV-1 associée à une vascularite paranéoplasique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
Legendre P, Chahwan D, Mohty M, Hermine O, Kahn J, Lortholary O, Bouscary D, Dougados M, Durand-Zaleski I, Godeau B, Mouthon L. Utilisation des immunoglobulines intraveineuses et sous-cutanées chez des patients atteints de déficits Immunitaires secondaires : analyse rétrospective (ULTIMATE). Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Rignault-Bricard R, Machavoine F, Mecheri S, Hermine O, Schneider E, Dy M, Leite-de-Moraes M. IL-3-producing basophils are required to exacerbate airway hyperresponsiveness in a murine inflammatory model. Allergy 2018; 73:2342-2351. [PMID: 29777594 DOI: 10.1111/all.13480] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/05/2018] [Indexed: 01/01/2023]
Abstract
BACKGROUND Basophils are commonly associated with allergic responses because of their ability to produce large amounts of pro-Th2 cytokines and histamine. However, the mechanisms through which bone marrow-resident basophils (BMRB) become fully competent cytokine and histamine producers in response to IgE crosslinking are poorly understood. Here, we sought to determine the role of IL-3 in promoting pro-Th2 basophils. METHODS BMRB and basophils exposed to IL-3 in vitro and in vivo were evaluated for their production of Th2 cytokines and histamine in response to FcεRI crosslinking on both protein and gene expression levels. In vivo relevance of our findings was assessed in a model of ovalbumin-induced allergic asthma using IL-3-deficient and wild-type mice in a protocol of adoptive basophil transfer. RESULTS We show that BMRB and basophils previously exposed to IL-3 differ in their ability to generate cytokines (IL-4, IL-6, IL-13, and GM-CSF) and histamine in response to FcεRI crosslinking, reflecting two stages of maturation. Exposure to IL-3 initiated an autocrine loop of endogenous IL-3 production that enhanced histamine and cytokine production upon FcεRI crosslinking. This increased responsiveness required calcium flux and was dependent on calcineurin and store-operated calcium channels. Our findings are of pathophysiological relevance, as assessed by the failure of IL-3-deficient mice to develop airway hyperreactivity, which could be restored by adoptive transfer of IL-3-derived basophils recovered from wild-type mice. CONCLUSION IL-3-dependent basophils promote Th2 allergic AHR, which designates the IL-3/basophil axis as a promising therapeutic target for the treatment of basophil-dependent asthma.
Collapse
Affiliation(s)
- R. Rignault-Bricard
- Laboratory of Immunoregulation and Immunopathology; Institut Necker-Enfants Malades; Centre National de la Recherche Scientifique (CNRS); Unité Mixte de Recherche (UMR) 8253; Institut National de la Santé et de la Recherche Médicale (Inserm) UMR 1151; Université Paris Descartes Sorbonne Paris Cité; Paris France
- Institut Imagine Inserm UMR1163; CNRS Equipe de Recherche Labelisée (ERL) 8654; Université Paris Descartes Paris; Paris France
| | - F. Machavoine
- Laboratory of Immunoregulation and Immunopathology; Institut Necker-Enfants Malades; Centre National de la Recherche Scientifique (CNRS); Unité Mixte de Recherche (UMR) 8253; Institut National de la Santé et de la Recherche Médicale (Inserm) UMR 1151; Université Paris Descartes Sorbonne Paris Cité; Paris France
| | - S. Mecheri
- Institut Pasteur; Unité de Biologie des Interactions Hôte Parasites; CNRS ERL9195, Inserm UMR1201; Paris France
| | - O. Hermine
- Institut Imagine Inserm UMR1163; CNRS Equipe de Recherche Labelisée (ERL) 8654; Université Paris Descartes Paris; Paris France
- Department of Hematology; Hôpital Necker Enfants Malades; Assistance Publique Hôpitaux de Paris; Université Paris Descartes Paris; Paris France
| | - E. Schneider
- Laboratory of Immunoregulation and Immunopathology; Institut Necker-Enfants Malades; Centre National de la Recherche Scientifique (CNRS); Unité Mixte de Recherche (UMR) 8253; Institut National de la Santé et de la Recherche Médicale (Inserm) UMR 1151; Université Paris Descartes Sorbonne Paris Cité; Paris France
| | - M. Dy
- Laboratory of Immunoregulation and Immunopathology; Institut Necker-Enfants Malades; Centre National de la Recherche Scientifique (CNRS); Unité Mixte de Recherche (UMR) 8253; Institut National de la Santé et de la Recherche Médicale (Inserm) UMR 1151; Université Paris Descartes Sorbonne Paris Cité; Paris France
| | - M. Leite-de-Moraes
- Laboratory of Immunoregulation and Immunopathology; Institut Necker-Enfants Malades; Centre National de la Recherche Scientifique (CNRS); Unité Mixte de Recherche (UMR) 8253; Institut National de la Santé et de la Recherche Médicale (Inserm) UMR 1151; Université Paris Descartes Sorbonne Paris Cité; Paris France
| |
Collapse
|
29
|
Meni C, Georgin-Lavialle S, Le Sachè de Peufeilhoux L, Jais J, Hadj-Rabia S, Bruneau J, Fraitag S, Hanssens K, Dubreuil P, Hermine O, Bodemer C. Paediatric mastocytosis: a 12-year follow-up cohort. Br J Dermatol 2018. [DOI: 10.1111/bjd.17169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Meni C, Georgin-Lavialle S, de Peufeilhoux LLS, Jais J, Hadj-Rabia S, Bruneau J, Fraitag S, Hanssens K, Dubreuil P, Hermine O, Bodemer C. 小儿肥大细胞增多症:一项为期 12 年的随访队列研究. Br J Dermatol 2018. [DOI: 10.1111/bjd.17180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Meni C, Georgin-Lavialle S, Le Saché de Peufeilhoux L, Jais JP, Hadj-Rabia S, Bruneau J, Fraitag S, Hanssens K, Dubreuil P, Hermine O, Bodemer C. Paediatric mastocytosis: long-term follow-up of 53 patients with whole sequencing of KIT. A prospective study. Br J Dermatol 2018; 179:925-932. [PMID: 29787623 DOI: 10.1111/bjd.16795] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/10/2018] [Indexed: 12/22/2022]
Abstract
BACKGROUND Mastocytosis is a heterogeneous group of clinical disorders characterized by the abnormal accumulation of mast cells. The adult and paediatric forms differ in their clinical and genetic features and outcomes. OBJECTIVES To describe the clinical evolution of a well-characterized cohort of paediatric mastocytosis (PM), and to analyse the relationship between KIT mutation and the clinical course. METHODS This was a prospective cohort study performed at the National Clinical Reference Center for Mastocytosis. Diagnosis was confirmed by identification of KIT mutation on lesional skin biopsy. Mastocytosis subtype, mast cell mediator-related symptoms (MC MRS) and clinical course were recorded. Fifty-three patients with PM and > 4 years of disease course were enrolled. The mean ± SD age at the final evaluation was 13·2 ± 4·8 years. The main outcome was the type of KIT mutation as a predictor of evolution and clinical characteristics. RESULTS Patients presented with maculopapular cutaneous mastocytosis (n = 44), diffuse cutaneous mastocytosis (n = 6) or mastocytoma (n = 3). The mean duration of disease was 12·1 years. Substantial or partial cutaneous regression (18 of 53 and 16 of 53), stabilization or aggravation (16 of 53) and complete cutaneous regression (three of 53) were noted. MC MRS mainly regressed (21 of 53). For 22 patients, evolution of MC MRS and evolution of cutaneous lesions were different. No significant association between evolution and KIT mutation or between evolution and type of cutaneous mastocytosis was found. A late onset of the disease (after 2 years) is associated with worse evolution. CONCLUSIONS PM is not systematically self-regressive. MC MRS manifestations and cutaneous lesions can persist or increase overtime. KIT mutation is not a predictor of evolution.
Collapse
Affiliation(s)
- C Meni
- Service de Dermatologie, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France.,Centre de reference des mastocytoses, CEREMAST, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France
| | - S Georgin-Lavialle
- Service de Médecine Interne, Hôpital Tenon, 20 rue de la Chine, 75020, Paris, France.,Faculté de Médecine, Université Pierre et Marie Curie, Paris, France
| | - L Le Saché de Peufeilhoux
- Service de Dermatologie, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France
| | - J P Jais
- Service de Biostatistiques, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France.,Faculté de Médecine, Université Paris Descartes, Paris Sorbonne Cité, Paris, France
| | - S Hadj-Rabia
- Service de Dermatologie, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France.,Faculté de Médecine, Université Paris Descartes, Paris Sorbonne Cité, Paris, France.,Inserm U1163, Institut Imagine, 149 rue des Sèvres, 75743, Paris, Cedex, 15, France
| | - J Bruneau
- Faculté de Médecine, Université Paris Descartes, Paris Sorbonne Cité, Paris, France.,Service d'Anatomie et Cytologie Pathologiques, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France
| | - S Fraitag
- Service d'Anatomie et Cytologie Pathologiques, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France
| | - K Hanssens
- Centre de reference des mastocytoses, CEREMAST, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France.,Inserm U1068, CRCM, Signaling, Hematopoiesis and Mechanism of Oncogenesis, Institut Paoli-Calmettes, Université d'Aix-Marseille, F-13284, CNRS, UMR7258, Marseille, F-13009, France
| | - P Dubreuil
- Centre de reference des mastocytoses, CEREMAST, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France.,Inserm U1068, CRCM, Signaling, Hematopoiesis and Mechanism of Oncogenesis, Institut Paoli-Calmettes, Université d'Aix-Marseille, F-13284, CNRS, UMR7258, Marseille, F-13009, France
| | - O Hermine
- Centre de reference des mastocytoses, CEREMAST, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France.,Faculté de Médecine, Université Paris Descartes, Paris Sorbonne Cité, Paris, France.,Inserm U1163, Institut Imagine, 149 rue des Sèvres, 75743, Paris, Cedex, 15, France.,CNRS ERL 8254 and Laboratory of Physiopathology and Treatment of Hematological Disorders, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France.,Service d'Hématologie Adultes, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France
| | - C Bodemer
- Service de Dermatologie, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France.,Centre de reference des mastocytoses, CEREMAST, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743, Paris, Cedex, 15, France.,Faculté de Médecine, Université Paris Descartes, Paris Sorbonne Cité, Paris, France.,Inserm U1163, Institut Imagine, 149 rue des Sèvres, 75743, Paris, Cedex, 15, France
| |
Collapse
|
32
|
Gridel C, Chandesris O, Mahlaoui N, Salvator H, Rivaud E, Picard C, Moshous D, Lortholoray O, Blanche S, Lanternier F, Neven B, Fischer A, Hermine O, Duréault A, Poirée S, Couderc L, Catherinot E, Tcherakian C. Manifestations pulmonaires chez les patients adultes avec syndrome hyper IgE STAT3 muté : résultats de la cohorte française. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Belz A, Salvator H, Catherinot E, Rivaud E, Chabrol A, Nguyen S, Suarez F, Hermine O, Longchampt E, Zemoura L, Chabi-Charvillat M, Tcherakian C, Couderc L. Pneumopathies interstitielles non infectieuses post allogreffe de cellules souches hématopoïétiques : série de 40 patients explorés à l’hôpital Foch. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Sbeih N, Hoyeau-Idrissi N, Fraisse T, Launay J, Hentgen V, Hermine O, Canioni D, Amselem S, Giurgea I, Louvrier C, Grateau G, Georgin Lavialle S. Implication des mastocytes dans la fièvre méditerranéenne familiale : une étude prospective sur 50 patients. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
35
|
Flores C, Hermine O, Maciel T, Rignault R, Rossignol J, Lepelletier Y. The immune modulation role of low dosage of cyclosporin-A (ldCSA) in the antitumor response of CD8+ T lymphocytes (CD8+Tcells) and the implication of neuropilin-1 (Nrp1). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx711.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Mahevas T, Jachiet M, Servy A, Livideanu CB, Cribier B, Frances C, Le Moigne M, Sbidian E, Bouaziz JD, Descamps V, D’incan M, Humbert P, Beylot-Barry M, Passeron T, Arnulf B, Harel S, Sassolas B, de Moreuil C, Hermine O, Dupuy A, Barbarot S, Debardieux S, Carpentier O, Brault F, Schmutz JL, Thomas-Beaulieu D, Zarnitsky C, Limal N, Le-Bras F, Osio A, Battistella M, Tauber M, Mékinian A, Fain O. Caractéristiques clinicobiologiques, facteurs pronostiques et prise en charge thérapeutique du scléromyxœdème : étude rétrospective multicentrique. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Laroche L, Bruneau J, Zuber J, Alanio C, Leclerc-Mercier S, Belaid Z, Kraft A, Roulot D, Roque AM, Wedemeyer H, Pol S, Hillion P, Hermine O, Mallet V. Régression d’une lymphoprolifération CD30+ après traitement antiviral pour une hépatite E chronique. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
38
|
Méni C, Sissaoui S, Bellon N, De Peufeilhoux L, Lacaille F, Hadj Rabia S, Hermine O, Bodemer C. Intérêt du séquençage complet du gène KIT dans la prise en charge des mastocytoses pédiatriques sévères. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Valent P, Akin C, Hartmann K, George TI, Sotlar K, Peter B, Gleixner KV, Blatt K, Sperr WR, Manley PW, Hermine O, Kluin-Nelemans HC, Arock M, Horny HP, Reiter A, Gotlib J. Midostaurin: a magic bullet that blocks mast cell expansion and activation. Ann Oncol 2017; 28:2367-2376. [PMID: 28945834 PMCID: PMC7115852 DOI: 10.1093/annonc/mdx290] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Clinically relevant features in patients with systemic mastocytosis (SM) include the cosmetic burden of lesional skin, mediator-related symptoms, and organ damage resulting from mast cell (MC) infiltration in advanced forms of SM. Regardless of the SM variant, expansion of neoplastic MC in the skin and other organs is triggered by mutant forms of KIT, the most prevalent being D816V. Activation of MC with subsequent release of chemical mediators is often caused by IgE-dependent mechanisms in these patients. Midostaurin, also known as PKC412, blocks the kinase activity of wild-type KIT and KIT D816V, counteracts KIT-dependent growth of neoplastic MC, and inhibits IgE-dependent mediator secretion. Based on this activity-profile, the drug has been used for treatment of patients with advanced SM. Indeed, encouraging results have been obtained with the drug in a recent multi-center phase II trial in patients with advanced SM, with an overall response rate of 60% and a substantial decrease in the burden of neoplastic MC in various organs. Moreover, midostaurin improved the overall survival and relapse-free survival in patients with advanced SM compared with historical controls. In addition, midostaurin was found to improve mediator-related symptoms and quality of life, suggesting that the drug may also be useful in patients with indolent SM suffering from mediator-related symptoms resistant to conventional therapies or those with MC activation syndromes. Ongoing and future studies will determine the actual value of midostaurin-induced MC depletion and MC deactivation in these additional indications.
Collapse
Affiliation(s)
- P Valent
- Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria;; Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria;.
| | - C Akin
- Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, USA
| | - K Hartmann
- Department of Dermatology, University of Luebeck, Luebeck, Germany
| | - T I George
- Department of Pathology, University of New Mexico, Albuquerque, USA
| | - K Sotlar
- Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria
| | - B Peter
- Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria;; Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - K V Gleixner
- Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria;; Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - K Blatt
- Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria;; Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - W R Sperr
- Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria;; Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | | | - O Hermine
- Centre National de Référence des Mastocytoses, Imagine Institute Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - H C Kluin-Nelemans
- Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - M Arock
- LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, Cachan, France
| | - H-P Horny
- Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany
| | - A Reiter
- Department of Hematology and Oncology, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany
| | - J Gotlib
- Stanford University School of Medicine/Stanford Cancer Institute, Stanford, USA
| |
Collapse
|
40
|
Kocic I, Sztormowska K, Jankowski Z, Mansfield C, Moussy A, Hermine O, Hermine O, Hermine O, Hermine O, Hermine O, Hermine O. P1342Protective effect of masitinib on cardiovascular function of rats with pulmonary hypertension: gender dependence. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1342] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Abbara S, Georgin-Lavialle S, Bachmeyer C, Hermine O, Launay JM, de Lastours V. [Chronic asthenia and abdominal pain in a 26-year-old woman]. Rev Med Interne 2017; 38:850-852. [PMID: 28755907 DOI: 10.1016/j.revmed.2017.06.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Accepted: 06/20/2017] [Indexed: 11/25/2022]
Affiliation(s)
- S Abbara
- Service de médecine interne, hôpital Tenon, université Paris-VI, DHUI2B, 4, rue de la Chine, 75020 Paris, France
| | - S Georgin-Lavialle
- Service de médecine interne, hôpital Tenon, université Paris-VI, DHUI2B, 4, rue de la Chine, 75020 Paris, France.
| | - C Bachmeyer
- Service de médecine interne, hôpital Tenon, université Paris-VI, DHUI2B, 4, rue de la Chine, 75020 Paris, France
| | - O Hermine
- Service d'hématologie adulte, centre de référence des mastocytoses, Inserm U1163 and CNRS ERL 8254, université Paris-Descartes, Sorbonne Paris-Cité, hôpital Necker-Enfants-malades, 149, rue de Sèvres, Fondation Imagine, 75015 Paris, France
| | - J-M Launay
- Laboratoire de biochimie et biologie moléculaire, hôpital Lariboisière, Inserm U942, RTRS santé mentale, université Paris-VII, 2, rue Ambroise-Paré, 75475 Paris cedex 10, France
| | - V de Lastours
- Service de médecine interne, hôpital Beaujon, AP - HP, 100, boulevard du Général-Leclerc, 92110 Clichy, France
| |
Collapse
|
42
|
Boddaert N, Salvador A, Chandesris MO, Lemaître H, Grévent D, Gauthier C, Naggara O, Georgin-Lavialle S, Moura DS, Munsch F, Jaafari N, Zilbovicius M, Lortholary O, Gaillard R, Hermine O. Neuroimaging evidence of brain abnormalities in mastocytosis. Transl Psychiatry 2017; 7:e1197. [PMID: 28786975 PMCID: PMC5611717 DOI: 10.1038/tp.2017.137] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 04/06/2017] [Accepted: 04/20/2017] [Indexed: 01/08/2023] Open
Abstract
Mastocytosis is a rare disease in which chronic symptoms are related to mast cell accumulation and activation. Patients can display depression-anxiety-like symptoms and cognitive impairment. The pathophysiology of these symptoms may be associated with tissular mast cell infiltration, mast cell mediator release or both. The objective of this study is to perform morphological or functional brain analyses in mastocytosis to identify brain changes associated with this mast cell disorder. We performed a prospective and monocentric comparative study to evaluate the link between subjective psycho-cognitive complaints, psychiatric evaluation and objective medical data using magnetic resonance imaging with morphological and perfusion sequences (arterial spin-labeled perfusion) in 39 patients with mastocytosis compared with 33 healthy controls. In the test cohort of 39 mastocytosis patients with psycho-cognitive complaints, we found that 49% of them had morphological brain abnormalities, mainly abnormal punctuated white matter abnormalities (WMA). WMA were equally frequent in cutaneous mastocytosis patients and indolent forms of systemic mastocytosis patients (42% and 41% of patients with WMA, respectively). Patients with WMA showed increased perfusion in the putamen compared with patients without WMA and with healthy controls. Putamen perfusion was also negatively correlated with depression subscores. This study demonstrates, for we believe the first time, a high prevalence of morphological and functional abnormalities in the brains of mastocytosis patients with neuropsychiatric complaints. Further studies are required to determine the mechanism underpinning this association and to ascertain its specificity.
Collapse
Affiliation(s)
- N Boddaert
- Department of Pediatric Radiology, Hôpital Necker-Enfants Malades, AP-HP, University René Descartes, PRES Sorbonne Paris Cité, INSERM U1000 and UMR 1163, Institut Imagine, Paris, France,Department of Pediatric Radiology, Hôpital Necker-Enfants Malades, AP-HP, University René Descartes, PRES Sorbonne Paris Cité, INSERM U1000 and UMR 1163, Institut Imagine, 149 rue de Sèvres, 75015 Paris, France. E-mail:
| | - A Salvador
- Laboratoire de “Physiopathologie des Maladies Psychiatriques”, Centre de Psychiatrie et Neurosciences U894, INSERM, Université Paris Descartes, Sorbonne Paris Cité, Paris, France,Service de Psychiatrie, Centre Hospitalier Sainte-Anne, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine Paris Descartes, Paris, France
| | - M O Chandesris
- Centre de Référence des Mastocytoses, Université Paris Descartes, Sorbonne, Paris Cité, Hôpital Necker-Enfants Malades, Fondation Imagine, Paris, France,Service d'Hématologie Adulte, Université Paris Descartes, Sorbonne, Paris Cité, Assistance Publique-Hôpitaux de Paris, Institut Imagine, Hôpital Necker-Enfants Malades, Paris, France
| | - H Lemaître
- Department of Pediatric Radiology, Hôpital Necker-Enfants Malades, AP-HP, University René Descartes, PRES Sorbonne Paris Cité, INSERM U1000 and UMR 1163, Institut Imagine, Paris, France
| | - D Grévent
- Department of Pediatric Radiology, Hôpital Necker-Enfants Malades, AP-HP, University René Descartes, PRES Sorbonne Paris Cité, INSERM U1000 and UMR 1163, Institut Imagine, Paris, France
| | - C Gauthier
- Service de Psychiatrie, Centre Hospitalier Sainte-Anne, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine Paris Descartes, Paris, France
| | - O Naggara
- Department of Neuroradiology, Service Hospitalo-Universitaire, Centre Hospitalier Sainte-Anne, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR894, Paris, France
| | - S Georgin-Lavialle
- Centre de Référence des Mastocytoses, Université Paris Descartes, Sorbonne, Paris Cité, Hôpital Necker-Enfants Malades, Fondation Imagine, Paris, France,INSERM U1163 and CNRS ERL 8254 and Laboratory of Physiopathology and Treatment of Hematological Disorders, Hôpital Necker-Enfants Malades, Paris, France,Service de Médecine Interne, Hôpital Tenon, Université Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - D S Moura
- Centre de Référence des Mastocytoses, Université Paris Descartes, Sorbonne, Paris Cité, Hôpital Necker-Enfants Malades, Fondation Imagine, Paris, France,INSERM U1163 and CNRS ERL 8254 and Laboratory of Physiopathology and Treatment of Hematological Disorders, Hôpital Necker-Enfants Malades, Paris, France,Laboratoire de Psychopathologie et Processus de Santé, EA 4057, IUPDP, Institut de Psychologie, Université Paris Descartes, Paris, France
| | - F Munsch
- MRI France GE Healthcare, Vélizy Villacoublay, France and Université de Bordeaux, Bordeaux, France,Inserm U1215 - Neurocentre Magendie, Bordeaux, France
| | - N Jaafari
- Unité de Recherche Clinique Intersectorielle en Psychiatrie à Vocation Régionale Pierre Deniker du Centre Hospitalier Henri Laborit, INSERM CIC-P 1402, INSERM U 1084 Laboratoire Expérimental et Clinique en Neurosciences, Univ Poitiers, CHU Poitiers, Groupement De Recherche CNRS 3557, Poitiers, France
| | - M Zilbovicius
- Department of Pediatric Radiology, Hôpital Necker-Enfants Malades, AP-HP, University René Descartes, PRES Sorbonne Paris Cité, INSERM U1000 and UMR 1163, Institut Imagine, Paris, France
| | - O Lortholary
- Centre de Référence des Mastocytoses, Université Paris Descartes, Sorbonne, Paris Cité, Hôpital Necker-Enfants Malades, Fondation Imagine, Paris, France,Infectious Diseases Unit, Necker-Enfants Malades Hospital, AP-HP Paris, Paris, France,Paris Descartes University, Imagine Institute, Paris, France
| | - R Gaillard
- Laboratoire de “Physiopathologie des Maladies Psychiatriques”, Centre de Psychiatrie et Neurosciences U894, INSERM, Université Paris Descartes, Sorbonne Paris Cité, Paris, France,Service de Psychiatrie, Centre Hospitalier Sainte-Anne, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine Paris Descartes, Paris, France,Centre de Référence des Mastocytoses, Université Paris Descartes, Sorbonne, Paris Cité, Hôpital Necker-Enfants Malades, Fondation Imagine, Paris, France,Human Histopathology and Animal Models, Infection and Epidemiology Department, Institut Pasteur, Paris, France
| | - O Hermine
- Centre de Référence des Mastocytoses, Université Paris Descartes, Sorbonne, Paris Cité, Hôpital Necker-Enfants Malades, Fondation Imagine, Paris, France,Service d'Hématologie Adulte, Université Paris Descartes, Sorbonne, Paris Cité, Assistance Publique-Hôpitaux de Paris, Institut Imagine, Hôpital Necker-Enfants Malades, Paris, France,INSERM U1163 and CNRS ERL 8254 and Laboratory of Physiopathology and Treatment of Hematological Disorders, Hôpital Necker-Enfants Malades, Paris, France
| |
Collapse
|
43
|
Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28:iv62-iv71. [PMID: 28881919 DOI: 10.1093/annonc/mdx223] [Citation(s) in RCA: 176] [Impact Index Per Article: 25.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Affiliation(s)
- M Dreyling
- Department of Medicine III, University Hospital - LMU Munich, Munich, Germany
| | - E Campo
- Hematopathology Section, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - O Hermine
- Department of Hematology, Imagine Institute and Descartes University, INSERM U1163 and CNRS ERL 8564, Necker Hospital, Paris, France
| | - M Jerkeman
- Department of Hematology, University Lund, Lund, Sweden
| | - S Le Gouill
- CHU de Nantes, Service d'Hématologie Clinique, Université de Nantes, Nantes, France
| | - S Rule
- Peninsula School of Medicine and Dentistry, University of Plymouth, Plymouth, UK
| | - O Shpilberg
- Institute of Hematology, Assuta Medical Center, Tel-Aviv, Israel
| | - J Walewski
- Department of Lymphoid Malignancy, Maria Sklodowska-Curie Institute and Oncology Centre, Warsaw, Poland
| | - M Ladetto
- Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| |
Collapse
|
44
|
|
45
|
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker L, Salles G, Tilly H, Lamy T, Gressin R, Hermine O. Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_74] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
| | - C. Thieblemont
- Hemato-Oncologie, APHP, Hôpital Saint-Louis; Paris France
| | - L. Oberic
- Hématologie, IUCT Oncopole; Toulouse France
| | - A. Moreau
- Hématologie, CHU De Nantes; Nantes France
| | | | | | - G. Damaj
- Hématologie, CHU Caen; Caen France
| | | | | | | | | | | | - C. Haioun
- hématologie, CHU Creteil; Creteil France
| | | | | | - O. Tournilhac
- Hématologie, CHU Clermont-Ferrand; Clermont-Ferrand France
| | - K. Le Dû
- Hématologie, Clinique Victor Hugo; Le Mans France
| | | | - G. Cartron
- hématologie, CHU Montpellier; Montpellier France
| | | | - G. Salles
- Hématologie, AP-HL Lyon; Lyon France
| | - H. Tilly
- hématologie, Centre Becquerel; Rouen France
| | - T. Lamy
- Hématologie, CHU Rennes; Rennes France
| | - R. Gressin
- Hématologie, CHU Grenoble; Grenoble France
| | - O. Hermine
- Hématologie, AP-HP Necker Paris; Paris France
| |
Collapse
|
46
|
Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, Trinquand A, Lhermitte L, Brousse N, Suarez F, Frenzel L, Delarue R, Marçais A, Macintyre E, Asnafi V, Lhospice F, Bonnafous C, Molina T, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O. NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_26] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Cheminant
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - J. Bruneau
- Pathology Department, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - G. Malamut
- Gastroenterology, HEGP Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - D. Sibon
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - N. Guegan
- INSERM UMR1163, Laboratory of Intestinal Immunity; Institut Imagine; Paris France
| | - A. Trinquand
- Biological Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - L. Lhermitte
- Biological Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - N. Brousse
- Pathology Department, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - F. Suarez
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - L. Frenzel
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - R. Delarue
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - A. Marçais
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - E. Macintyre
- Biological Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - V. Asnafi
- Biological Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - F. Lhospice
- Innate Pharma; Innate Pharma; Marseille France
| | | | - T. Molina
- Pathology Department, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - B. Meresse
- INSERM UMR1163, Laboratory of Intestinal Immunity; Institut Imagine; Paris France
| | - C. Cellier
- Gastroenterology, HEGP Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - N. Cerf-Bensussan
- INSERM UMR1163, Laboratory of Intestinal Immunity; Institut Imagine; Paris France
| | - O. Hermine
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| |
Collapse
|
47
|
Aukema S, Hoster E, Rosenwald A, Canoni D, Rymkiewicz G, Thorns C, Hartmann S, Kluin-Nelemans H, Hermine O, Dreyling M, Klapper W. P53 BUT NOT SOX11 IHC HAS PROGNOSTIC VALUE INDEPENDENT OF MIPI AND KI-67 IN PROSPECTIVE TRIALS OF THE EUROPEAN-MCL NETWORK. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_129] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S.M. Aukema
- Dept. of Pathology and Hematopathology Section and Lymph Node Registry; Christian Albrechts University of Kiel; Kiel Germany
| | - E. Hoster
- Department of Internal Medicine III; University Hospital Munich; Munich Germany
| | - A. Rosenwald
- Department of Pathology; University of Würzburg; Würzburg Germany
| | - D. Canoni
- Department of Pathology, Hôpital Necker; Assistance Publique Hôpitaux de Paris; Paris France
| | - G. Rymkiewicz
- Department of Pathology; The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology; Warsaw Poland
| | - C. Thorns
- Department of Pathology; University Hospital Schleswig-Holstein, Lübeck; Lübeck Germany
| | - S. Hartmann
- Department of Pathology; University Hospital of Frankfurt; Frankfurt am Main Germany
| | - H.C. Kluin-Nelemans
- Department of Hematology; University Medical Center Groningen; Groningen Netherlands
| | - O. Hermine
- Department of Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris; University Paris Descartes; Paris France
| | - M. Dreyling
- Department of Internal Medicine III; University Hospital Munich; Munich Germany
| | - W. Klapper
- Dept. of Pathology and Hematopathology Section and Lymph Node Registry; Christian Albrechts University of Kiel; Kiel Germany
| |
Collapse
|
48
|
Ribrag V, Feugier P, Doorduijn J, Delfau-Larue M, Hermine O, Kluin-Nelemans H, Dasilva M, Lopez-Hernandez A, Walewski J, Szymczyk M, Pott C, Homburg C, Van der Velden V, Gameiro P, Garcia-Sanz R, Ladetto M, van Krieken H, Cabeçadas J, Rymkiewicz G, Klapper W, Hoster E, Le Gouill S, Dreyling M. MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK
ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND a RITUXIMAB-LENALIDOMIDE MAINTENANCE. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- V. Ribrag
- Hematology; Gustave Roussy Cancer Campus; Villejuif France
| | - P. Feugier
- Hematology; Hôpitaux De Brabois; Vandoeuvre-Les-Nancy France
| | - J. Doorduijn
- Hematology; Department of Hematology, Erasmus MC; Rotterdam Netherlands
| | - M. Delfau-Larue
- Hématologie et Immunologie Biologiques; GH Henri Mondor; Creteil France
| | - O. Hermine
- Hematology; Groupe Hospitalier : Hôpital Universitaire Necker-Enfants Malades; Paris France
| | - H. Kluin-Nelemans
- Department of Hematology; University Medical Center Groningen, University of Groningen; Groningen Netherlands
| | - M. Dasilva
- Serviço De Hematologia; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | | | - J. Walewski
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - M. Szymczyk
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - C. Pott
- Klinisch-Experimentelle Hämatologie; Universitätsklinikum Schleswig-Holstein; Kiel Germany
| | - C. Homburg
- Laboratoriumhoofd Immunocytologie; Sanquin Diagnostiek; Amsterdam Netherlands
| | - V. Van der Velden
- Hematology; Department of Hematology, Erasmus MC; Rotterdam Netherlands
| | - P. Gameiro
- Biologia Molecular Laboratório De Hemato-Oncologia; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | | | - M. Ladetto
- Hematology; Azienda Ospedaliera Nazionale SS.Antonio e Biagio e C. Arrigo; Alessandria Italy
| | - H. van Krieken
- Pathology; Radboud University Medical Center; Nijmegen Netherlands
| | - J. Cabeçadas
- Serviço De Anatomia Patológica; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | - G. Rymkiewicz
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - W. Klapper
- Institut Für Pathologie, Sektion Hämatopathologie und Lymphknotenregister; Universitätsklinikum Schleswig-Holstein, Campus Kiel; Kiel Germany
| | - E. Hoster
- Department of Medicine III; University Hospital of Munich; Munich Germany
| | - S. Le Gouill
- Service d'Hématologie; CHU de Nantes; Nantes France
| | - M. Dreyling
- Department of Medicine III; University Hospital of Munich; Munich Germany
| |
Collapse
|
49
|
Frigeni M, Visco C, Besson C, Rattotti S, Fontaine H, Goldaniga M, Visentini M, Torres H, Peveling-Oberhag J, Rossotti R, Zaja F, Rigacci L, Merli M, Dorival C, Alric L, Piazza F, Gentile M, Ferrari A, Pirisi M, Tedeschi A, Defrancesco I, Ferretti V, Bruno R, Hermine O, Arcaini L. INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Frigeni
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - C. Visco
- Department of Cell Therapy and Hematology; San Bortolo Hospital; Vicenza Italy
| | - C. Besson
- Université Paris Sud, INSERM; Assistance Publique-Hôpitaux de Paris Centre Hospitalier Universitaire Bicêtre; Le Kremlin-Bicêtre France
| | - S. Rattotti
- Department of Hematology Oncology; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| | - H. Fontaine
- Paris 5 Descartes University; INSERM U1213 and Unité Mixte de Service 20; Institut Pasteur, Department of Hepatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Paris France
| | - M. Goldaniga
- Department of Hematology, Fondazione Ospedale Maggiore Policlinico; Mangiagalli e Regina Elena; Milan Italy
| | - M. Visentini
- Division of Clinical Immunology; Sapienza University of Rome, Fondazione Roma; Rome Italy
| | - H.A. Torres
- Department of Infectious Diseases, Infection Control, and Employee Health; The University of Texas MD Anderson Cancer Center; Houston Texas USA
| | - J. Peveling-Oberhag
- Department of Internal Medicine 1; Goethe-University Hospital; Frankfurt Germany
| | - R. Rossotti
- Department of Infectious Diseases; Ospedale Niguarda Ca’ Granda; Milan Italy
| | - F. Zaja
- Hematology Unit, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Sanitaria Universitaria Integrata; Udine Italy
| | - L. Rigacci
- Department of Hematology; Azienda Ospedaliero-Universitaria Careggi; Florence Italy
| | - M. Merli
- Division of Hematology, Ospedale di Circolo e Fondazione Macchi; University of Insubria; Varese Italy
| | - C. Dorival
- Sorbonne Universités, Pierre and Marie Curie University (University of Paris 06), INSERM; Institut Pierre Louis d'épidémiologie et de Santé Publique (Unité mixte de recherche S1136); Paris France
| | - L. Alric
- Toulouse 3 University, Unité mixte de recherche 152 Institut de Recherche pour le Développement; Department of Internal Medicine and Digestive Diseases, Hôpital Purpan; Toulouse France
| | - F. Piazza
- Hematology and Clinical Immunology Unit, Department of Medicine; University of Padua; Padua Italy
| | - M. Gentile
- Hematology Unit; Azienda Ospedaliera di Cosenza; Cosenza Italy
| | - A. Ferrari
- Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico; Reggio Emilia Italy
| | - M. Pirisi
- Department of Translational Medicine; Università degli Studi del Piemonte Orientale "A. Avogadro"; Novara Italy
| | - A. Tedeschi
- Department of Hematology, Niguarda Cancer Center, Ospedale Niguarda Ca’ Granda; Milan Italy
| | - I. Defrancesco
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - V.V. Ferretti
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - R. Bruno
- Division of Infectious and Tropical Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| | - O. Hermine
- Paris 5 Descartes University; AP-HP, Department of Adult Hematology and Imagine Institute, Hôpital Necker; Paris France
| | - L. Arcaini
- Department of Hematology Oncology; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| |
Collapse
|
50
|
Didier M, Mahlaoui N, Oksenhendler E, Fischer A, Blanche S, Neven B, Moshous D, Suarez F, Hermine O, Salvator H, Rivaud E, Devillier P, Catherinot E, Couderc LJ. Dilatations des bronches chez les adultes atteints de déficits immunitaires héréditaires humoraux diagnostiqués dans l’enfance. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|